The significance and treatment of antiphospholipid antibodies;Les anticorps antiphospholipides, signification et traitement

Presse Medicale

Volumn 33, Issue 14 I, 2004, Pages 944-952

  Godeau, Bertrand ^a   Piette, Jean Charles ^b  

^a HENRI MONDOR HOSPITAL   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CARDIOLIPIN ANTIBODY; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; STEROID;

ANTIPHOSPHOLIPID SYNDROME; ARTERY EMBOLISM; FETUS WASTAGE; HUMAN; MULTIPLE ORGAN FAILURE; PLASMA CELL; REVIEW; SPONTANEOUS ABORTION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; VENOUS THROMBOEMBOLISM;

EID: 4444380444     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(04)98805-7     Document Type: Review

References (51)

1. e édition, Godeau P, Herson S, Piette JC eds Flammarion, Paris 2004: 148-53.
2. Sibila J. Syndrome des antiphospholipides: pourquoi faut-il y penser et comment faire le diagnostic? Rev Rhum 2003; 70: 228-34.
3. Ruiz-Irastorza G, Khamashta M, Hughes GRV. Hughes syndrome crosses boundaries. Autoimmun Rev 2002; 1: 43-8.
4. Wilson WA Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-11.
5. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
6. Akimoto T, Akama T, Saitoh M, Kono I, Sumida T. Antiprothrombin autoantibodies in severe preeclampsia and abortion. Am J Med 2001; 110: 188-91.
7. Rand JH. Antiphospholipid antibody-mediated disruption of the annexin-V antithrombotic shield: a thrombogenic mechanism for the antiphospholipid syndrome. J Autoimmun 2000; 15: 107-11.
8. Lockshin MD, Sammaritano LR, Schwartzman S. Validation of the Sapporo criteria for antiphospholipid syndrome. Arthritis Rheum 2000; 43: 440-3.
9. Weber M, Hayem G, Meyer O. The Sapporo criteria for antiphospholipid syndrome: comment on the article by Lockshin et al. Arthitis Rheum 2001; 44: 1965-6.
10. Kmic-Barrie S, O'Connor CR, Looney SW, Pierangeli SS, Harris EN. A retrospective review of 61 patients with antiphospholipid syndrome. Analysis of factors influencing recurrent thrombosis. Arch Intern Med 1997; 157: 2101-8.
11. Baglin T, Luddington R, Brown K, Baglin C. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-6.
12. Piette JC, Amoura Z, Wechsler B. Syndromes des antiphospholipides. In: Atteintes neurologiques au cours des maladies systémiques. Déchy H, Wechsler B, Hausfater P, Rancurel G, Piette JC eds. Flammarion Médecine-Sciences, Paris 2003: 148-53.
13. Frances C, Papo T, Wechsler B, Laporte JL, Biousse V, Piette JC. Sneddon syndrome with or without antiphospholipid antibodies. A comparative study in 46 patients. Medicine 1999; 78: 209-19.
14. Brey R. Differential diagnosis of central nervous system manifestations of the antiphospholipid antibody syndrome. J Autoimmun 2000; 15: 133-8.
15. Ruiz-Irastorza G, Khamasta MA. Warfarin for multiple sclerosis? Q J Med 2000; 93: 497-9.
16. Mc Donald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
17. Nochy D, Daugas E, Le Thi Huong D, Piette JC, Hill G. Kidney involvement in the antiphospholipid syndrome. J Autoimmun 2000; 15: 127-32.
18. Cacoub P, Wechsler B, Piette JC et al. Malignant hypertension in antiphospholipid syndrome withput overt lupus nephritis. On Exp Rheum 1993; 11: 479-85.
19. Espinosa G, Santos E, Cervera R et al. Adrenal involvement in the antiphospholipid syndrome. Clinical and immunologic characteristics of 86 patients. Medicine 2003; 82: 106-18.
20. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome: clinical and laboratary features of 50 patients. Medicine 1998; 77: 195-207.
21. Cervera R. Recent advances in antiphospholipid antibody-related valvulopathies. J Autoimmun 2000; 15: 123-5.
22. Laraki R, Blétry O, Wechsler B, Piette JC, de Zuttere D, Godeau R, Cœur et anticorps antiphospholipides. Expérience personnelle et revue de la littérature. Rev Med Interne 1996; 17: 46-57.
23. Piette JC, Amoura Z, Papo T. Valvular heart disease and systemic lupus erythematosus. N Engl J Med 1997; 336: 1324.
24. Meroni PL, Raschi E, Camera M et al. Endothelial activation by aPL: a potential pathogenetic mechanism for the clinical manifestation of the syndrome. J Autoimmun 2000; 15: 237-40.
25. Del Papa N, Guidali L, Sala A et al. Endothelial cell as target for antphospholipid antibodies. Arthritis Rheum 1997; 40; 551-61.
26. Lambert M, Boullier A, Hachulla E et al. Paraoxonase activity is dramatically decreased in patients positive for anticardiolipin antibodies. Lupus 2000; 9: 299-300.
27. Vignes S, Chaillet M, Cabane J, Piette JC. Perforation de la cloison nasale et maladies systémiques. Rev Méd Interne 2002; 23: 919-26.
28. Francès C, Piette JC. The mystery of Sneddon syndrome: relationship with antiphospholipid syndrome and systemic lupus erythematosus. J Autoimmun 2000; 15: 139-44.
29. Alarcon-Segovia D, Perez-Vazquez ME, Villa AR et al. Preliminary classification criteria for the antiphospholipid syndrome within systemic lupus erythematosus. Semin Arthritis Rheum 1992; 21: 275-86.
30. Godeau B, Piette JC, Fromont P, Intrator L, Schaeffer A, Bierling P. Specific antiplatelet glycoprotein autoantibodies are associated with the thrombocytopenia of primary antiphospholipid syndrome. Br J Haematol 1997; 98: 873-9.
31. Stasi R, Stipa E, Masi M et al. Prevalence and clinical significance of elevated antiphospholipid antibodies in patients with idiopathic thrombocytopenic purpura. Blood 1994; 84: 4203-8.
32. Diz-Kucukkaya R, Hacihanefioglu A, Yenerel M et al. Antiphospholipid antibodies and antiphospholipid syndrome in patients presenting with immune thrombocytopenic purpura: a prospective cohort study. Blood 2001; 98: 1760-4.
33. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347: 589-600.
34. Asherson RA, Cervera R, Piette JC et al. Catastrophic antiphospholipid syndrome. Clues to the pathogenesis from series of 80 patients. Medicine 2001; 80: 355-75.
35. Ruiz-Irastorza G, Khamasta M, Hughes GRV. Treatment of pregnancy loss in Hughes syndrome: a critical update. Autoimmun Rev 2002; 1: 298-304.
36. Sebire NJ, Backos M, El Gaddal S, Goldin RD, Legan L. Placenta pathology, antiphospholipid antibodies, and pregnancy outcome in recurrent miscarriage patients. Obstet Gynecol 2003; 101: 258-63.
37. Hachulla E, Leys D, Deleume JF, Pruvo JP, Devulder B, Manifestations neurologiques associées aux anticorps antiphospholipides. Ou que reste-t-il du neurolupus? Rev Med Interne 1995; 16: 121-30.
38. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
39. Alarcon-Segovia D, Pérez-Ruiz A, Villa AR. Long-term prognosis of antiphospholipid syndrome in patients with systemic lupus erythematosus. J Autoimmun 2000; 15: 157-61.
40. Lambert M. 10th International congress on antiphospholipid antibodies. Taormina, Sicile, Italie, septembre 2002. Rev Med Interne 2003; 24: 411-16.
41. Tan E, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982; 25: 1271-7.
42. Piette JC, Wechsler B, Frances C et al. Exclusion criteria for primary antiphospholipid syndrome. J Rheumatol 1993; 20: 1802-4.
43. Rosove MH, Brewer PMC. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 1992; 117: 303-8.
44. Khamashta M, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid syndrome. N Engl J Med 1995; 332: 993-7.
45. Crowther MA, Ginsberg JS, Julian J et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-8.
46. Lockshin MD, Erkan D. Treatment of the antiphospholipid syndrome. N Engl J Med 2003; 349: 1177-9.
47. Finazzi G, Marchioli R, Barbui T. A randomized clinical trial of two intensitis of oral anticoagulant therapy in patients with the antiphospholipid syndrome. Final results of the WAPS study. 45th congress of the American Society of Haematology, 2003, San Diego, USA.
48. Khamshta MA. Primary prevention of thrombosis in subjects with positive antiphospholipid antibodies. J Autoimmun 2000; 15: 249-53.
49. Branch DW, Peaceman AM, Druzin M et al. A multicenter, placebo-controlled pilot study of intravenous immune globulin treatment of antiphospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000; 182: 122-7.
50. Rai R, Cohen H, Dave M, Regan L. Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phopsholipid antibodies (or antiphospholipid antibodies). BMJ 1997; 314: 253-7.
51. Farquharson RG, Quenby S, Greaves M. Antiphospholipid syndrome in pregnancy: a ranndomized, controlled trial of treatment. Obstet Gynecol 2002; 100: 408-13.